2023-09-23 07:08:04
New Alzheimer’s Drug Leqembi Sparks Excitement at Neuro Conference
Bremen, Germany – A new drug for Alzheimer’s disease has been making waves at the “Neuro 2023” conference held at the Congress Center in Bremen. The drug, called Leqembi, has already been approved in the United States and is showing promising results in slowing down the progression of the disease in its early stages.
Unlike existing Alzheimer’s medications that only address the symptoms of the disease, Leqembi targets the underlying cause by supplying the patient with amyloid antibodies. These antibodies help wash out protein deposits in the brain that severely impair the brain functions of Alzheimer’s patients. By removing these deposits, damage to the nerve cells can be prevented, and the progression of the disease can be slowed down significantly.
“This is a revolution. The new drug intervenes in the disease process,” said Andreas Kastrup, chief physician in the Department of Neurology at the Bremen-Mitte Clinic and one of the developers of the “Neuro 2023” program. Kastrup believes that Leqembi will soon be approved in Germany, offering hope to those affected by Alzheimer’s.
However, Leqembi is not without its drawbacks. Clinical tests have shown that the drug can cause inflammatory reactions in the brain, and in rare cases, bleeding can occur. Additionally, the drug is most effective when administered in the early stages of Alzheimer’s, making early detection crucial. Furthermore, Leqembi comes with a hefty price tag of around 30,000 euros per year per patient, making it inaccessible for many.
Opinions among experts about the effectiveness of Leqembi vary. While Kastrup is optimistic about its potential, neurologist Holger Honig has doubts about the efficacy of amyloid antibodies in treating Alzheimer’s. Honig believes that supporting relatives is currently the most important aspect of Alzheimer’s care.
Aside from the discussions surrounding the new Alzheimer’s drug, the “Neuro 2023” conference also offers updates on Parkinson’s, multiple sclerosis, and dementia. With around two-thirds of the lectures aimed at laypeople, the event aims to provide information and support for those affected by these neurological diseases and their families.
The conference also includes a trade fair where attendees can learn about aids, therapies, clinics, and self-help groups related to neurological diseases. With 800 participants and 40 exhibitors, “Neuro 2023” is considered the largest training and information event for neurological diseases in Northern Germany.
For more information about the conference, visit the website “www.neuro-bremen.de.”]
#Neuro #Bremen #drug #slow #Alzheimers